Latest Conference Articles

Baricitinib Effectively Reduces Frequency of Flares in Patients with JIA

Baricitinib Effectively Reduces Frequency of Flares in Patients with JIA

June 15th 2022

EULAR European Congress of Rheumatology

The study, which assessed data from the JUVE-BASIS trial, suggests baricitinib significantly reduced both the time to and frequency of flares in patients with JIA when compared with placebo.

Gout Flares Predicted by Monosodium Urate Deposits, Subclinical Inflammation

Gout Flares Predicted by Monosodium Urate Deposits, Subclinical Inflammation

June 14th 2022

EULAR European Congress of Rheumatology

Differences among baseline clinical and laboratory characteristics between cases and controls were observed in those with a presence of subcutaneous tophi and higher serum urate levels.

Désirée van der Heijde, MD, PhD: Safety, Efficacy of Bimekizumab in Ankylosing Spondyloarthritis

Désirée van der Heijde, MD, PhD: Safety, Efficacy of Bimekizumab in Ankylosing Spondyloarthritis

June 14th 2022

EULAR European Congress of Rheumatology

Désirée van der Heijde, MD, PhD, explains the results of a recent trial evaluating the safety and efficacy of bimekizumab in patients with active ankylosing spondylitis.

Rheumatology Network's Top 5: June 11, 2022

Rheumatology Network's Top 5: June 11, 2022

June 11th 2022

EULAR European Congress of Rheumatology

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 11, 2022.

Frédéric Lavie, MD, PhD: Efficacy of Guselkumab Across Multiple Disease Domains of Psoriatic Arthritis

Frédéric Lavie, MD, PhD: Efficacy of Guselkumab Across Multiple Disease Domains of Psoriatic Arthritis

June 10th 2022

EULAR European Congress of Rheumatology

Frédéric Lavie, MD, PhD, explains the results of the data presented at EULAR evaluating guselkumab for the treatment of psoriatic arthritis.

Terence Rooney, MD: Innovative Aspects of Future-Facing Research in Psoriatic Arthritis

Terence Rooney, MD: Innovative Aspects of Future-Facing Research in Psoriatic Arthritis

June 9th 2022

EULAR European Congress of Rheumatology

Terence Rooney, MD, explains the innovative research methods that Janssen utilizes and the benefits of precision medicine in the treatment of psoriatic arthritis.

Guselkumab Improves Health-Related Quality of Life in Patients with PsA

Guselkumab Improves Health-Related Quality of Life in Patients with PsA

June 9th 2022

EULAR European Congress of Rheumatology

Terence Rooney, MD, discusses recent findings indicating that guselkumab provided patients with psoriatic arthritis with sustained improvements in health-related quality of life through 2 years.

Karin Schenck-Gustafsson, MD, PhD, FESC: Why Sex and Gender Must be Considered in Disease Treatment

Karin Schenck-Gustafsson, MD, PhD, FESC: Why Sex and Gender Must be Considered in Disease Treatment

June 8th 2022

EULAR European Congress of Rheumatology

Karin Schenck-Gustafsson, MD, PhD, FESC, explains why sex and gender must be taken into account when treating and managing patients with rheumatic disease from a cardiologist's perspective.

Line Uhrenholt, MD: Disease Activity-Guided Tapering in Patients with Inflammatory Arthritis

Line Uhrenholt, MD: Disease Activity-Guided Tapering in Patients with Inflammatory Arthritis

June 8th 2022

EULAR European Congress of Rheumatology

Line Uhrenholt, MD, discusses the results of her randomized, open-label, equivalence trial study evaluating disease activity-guided tapering of biologics in patients with inflammatory arthritis.

Patients with RA Hesitant to Make Changes to DMARD Therapy

Patients with RA Hesitant to Make Changes to DMARD Therapy

June 7th 2022

EULAR European Congress of Rheumatology

Investigators believe that treatment escalation within patients with rheumatoid arthritis should utilize interventions beyond the traditional physician-patient relationship.